基于“态靶辨证”论治原发性骨质疏松

Treating Primary Osteoporosis Based on “State-Target Discrimination”

摘要: 目前广泛认同的骨质疏松机制为骨重建失衡，针对此机制西药主要干预手段为抑制骨吸收及促骨形成药物的使用，但面临单用干预路径相对单一、联用价格昂贵的问题；随着现代药理学对中药单药及复方研究的深入，越来越多的证据表明中药具有诱导成骨细胞增殖分化、抑制破骨细胞形成、改善氧化应激等复合作用。为充分发挥中医药优势，本文基于仝小林院士“态靶结合”的辨治模式，提出围绕“肾虚为本”“少阳为枢”为干预核心，通过补肾壮骨与和解少阳并用以“纠态”，根据现代药理学研究指导选药“打靶”，恢复骨重建平衡的现代中药精准辨治思路。

Abstract: At present, it is widely accepted that the mechanism of osteoporosis is the imbalance of bone reconstruction. For this mechanism, the main means of intervention of western medicine are the inhibition of bone resorption and the use of pro-osteogenic drugs, but it faces the problem of relatively single path of intervention and expensive price of combination; with the in-depth research of modern pharmacology on Chinese medicine and compound prescription, more and more evidences show that Chinese medicine has the compound effect of inducing osteoblasts to proliferate and differentiate, inhibiting osteoclast formation, and improving oxidative stress. In order to give full play to the advantages of traditional Chinese medicine, this paper, based on the “state-target combination” treatment model of academician Tong Xiaolin, proposes to focus on “kidney deficiency as the basis” and “Shaoyang as the pivot” as the core of intervention, through the use of the “kidney deficiency as the basis” and “Shaoyang as the pivot” as the core of intervention, and the use of traditional Chinese medicine as the core of treatment, by tonifying the kidneys and reconciling Shaoyang to “correct the state”, and according to modern pharmacological research to guide the selection of medicines “hitting the target”, to restore the balance of bone reconstruction of the modern traditional Chinese medicine precise identification and treatment of the idea.